176 related articles for article (PubMed ID: 34100956)
21. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
22. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
[TBL] [Abstract][Full Text] [Related]
23. Perioperative therapies for urological cancers.
Inokuchi J; Yokomizo A; Nishiyama N; Kitamura H; Eto M; Nishiyama H; Tomita Y
Jpn J Clin Oncol; 2020 Apr; 50(4):357-367. PubMed ID: 32115649
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
25. Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.
Iacovelli R; Ciccarese C; Schutz FA; Tortora G; de Velasco G
Urol Oncol; 2020 Oct; 38(10):798.e17-798.e24. PubMed ID: 32773231
[TBL] [Abstract][Full Text] [Related]
26. Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management.
Rebhan K; Laukhtina E; Shariat SF; Gust KM
Curr Opin Urol; 2020 May; 30(3):457-466. PubMed ID: 32235284
[TBL] [Abstract][Full Text] [Related]
27. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
28. A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma.
Meng WS; Salgia NJ; Pham NB; Velankar KY; Pal SK
Urol Oncol; 2021 Jun; 39(6):338-345. PubMed ID: 32402767
[TBL] [Abstract][Full Text] [Related]
29. Present status and future perspective of peptide-based vaccine therapy for urological cancer.
Obara W; Kanehira M; Katagiri T; Kato R; Kato Y; Takata R
Cancer Sci; 2018 Mar; 109(3):550-559. PubMed ID: 29345737
[TBL] [Abstract][Full Text] [Related]
30. [Current concepts for perioperative systemic therapy in advanced renal cell carcinoma].
Hilser T; Kuczyk M; Darr C; Grünwald V
Urologie; 2022 Dec; 61(12):1345-1350. PubMed ID: 36418538
[TBL] [Abstract][Full Text] [Related]
31. Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Gao X; McDermott DF
Cancer J; 2018; 24(4):171-179. PubMed ID: 30119080
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitor Toxicity Management in Non-muscle-invasive Bladder Cancer: What Urologists Need To Know.
Davaro F; Jain R; Li R
Eur Urol Focus; 2023 Jul; 9(4):579-581. PubMed ID: 37202260
[TBL] [Abstract][Full Text] [Related]
33. Checkpoint inhibition: new treatment options in urologic cancer.
De Maeseneer DJ; Delafontaine B; Rottey S
Acta Clin Belg; 2017 Feb; 72(1):24-28. PubMed ID: 28151378
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
36. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective study.
Jammal N; Pan E; Hurwitz M; Abramovitz RB
J Oncol Pharm Pract; 2020 Apr; 26(3):556-563. PubMed ID: 31216241
[TBL] [Abstract][Full Text] [Related]
38. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
39. Patterns of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors.
Hunting JC; Faucheux AT; Price SN; Elko CA; Quattlebaum A; Bloomer C; Olson E; Petty WJ; Lycan TW
Immunotherapy; 2024 Apr; 16(6):381-390. PubMed ID: 38197144
[TBL] [Abstract][Full Text] [Related]
40. What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature.
Mori K; Schmidinger M; Quhal F; Egawa S; Shariat SF; Grünwald V
Curr Opin Urol; 2021 May; 31(3):276-284. PubMed ID: 33742984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
